News | March 19, 2026
Strides acquires generic brands from Sandoz to boost Africa business
The initial consideration for the transaction is US$ 12 million
The initial consideration for the transaction is US$ 12 million
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
SPARK has extended its influence to an additional 9.47 million students worldwide
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The company announced positive topline data from the Phase 3 ADorable-1 trial
Subscribe To Our Newsletter & Stay Updated
